Ajay Devgn, Saif Ali Khan, and Kajol starrer Tanhaji: The Unsung Warrior is undoubtedly one of the most awaited films of 2020. The trailer of the film was released a few days ago, and it has received a great response. While we have heard about Tanaji Malusare, we are sure many of you don’t have more details about him. So, let us tell you about the great warrior.
Tanaji was born in the 1600s in Godavli, Javali Taluka (Satara, Maharashtra, India). He was a commander of Maratha ruler Shivaji Maharaj. He was so loyal to Shivaji Maharaj that when in 1670 he was summoned by Chatrapati for a meeting, Tanaji decided to put the wedding plan of his son Rayaba on hold and went to meet him.
Mughals had captured the Kondhana fort near Pune which was controlled by Udaybhan Rathod (played by Saif Ali Khan in the film) and Shivaji Maharaj wanted to recapture the fort. Tanaji took up the charge to get the fort back. With an army of 800 people, Tanaji marched on to conquer Kondana fort.
He decided that along with a troop of 300 he would scale the fort from the western side on a dark night with the help of a domesticated Bengal monitor lizard (called ghorpad in Marathi) named Yashwanti. Well, they failed twice but then finally they successfully scaled the steep hill fortress.
After opening the Kalyan Darwaza, Tanaji, his men and another troop of 500 men headed by Suryaji (his younger brother) attacked the army holding down the fort. A fierce battle took place between them. During the battle, Tanaji broke his shield but he continued fighting.
Tanaji Malusare lost his life in the battle and Shelar Mama killed Udaybhan. The battle was won by Marathas and they took over the Kondana fort. The fort is now known as Sinhagad. When Shivaji Maharaj came to know about the courage and the death of his close friend and commander Tanaji, he said, ‘gad alaa pan sinha gelaa’ which translates to ‘the fort is captured but the lion (Tanaji Malusare) has died.’
Kondana fort was renamed as Sinhagad by Shivaji Maharaj in the name of his former commander and as a testimony of his sacrifice; his statue stands tall at the fort.
It will surely be interesting to watch this story on the big screen on 10th January 2020.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.